Biopeople member ExpreS2ion to lead European COVID-19 vaccine consortium for rapid clinical development
The consortium includes all the bench-to-bedside expertise required for rapid clinical development of the COVID-19 vaccine that is already under development by ExpreS2ion.
The aim of the consortium is to develop a COVID-19 vaccine candidate, including performing proof-of-concept non-human primate (NHP) challenge studies, as well as a Phase I/IIa clinical trial with an ambitious aim to initiate clinical investigations within 12 months.
The consortium members are world-leading experts in their respective fields, covering all relevant areas of viral research and vaccine development required for rapid clinical development of a COVID-19 vaccine. This includes pre-clinical and clinically validated experience from working with similar Coronaviruses such as MERS and SARS, ExpreS2ion’s Drosophila S2 insect cell expression system, AdaptVac’s Virus-Like Particle technology and international large-scale production capacity provided by AGC Biologics, with production sites in Denmark, Germany, the US and Japan.
ExpreS2ion Biotechnologies ApS was founded in 2010 as a spin out of the S2 expression platform from the Danish company Affitech A/S. The founders were scientists who had developed the platform as employees of initially Pharmexa A/S and following Affitech A/S. In 2016, ExpreS2ion Biotech Holding AB as founded.